IRDOpus Genetics, Inc.
$4.65+127% 1Y
$4.65
$1.7452 weeks$6.09
IRD in its own filings
IRD's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
403
Events found in the filings · across 1,055 filings · the record starts in 2004
- Hard flags
- 4
Hard flags
- Most recent filing
- Sep 11, 2026
Most recent filing · Form 8-K
- Record starts
- May 17, 2004
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- Restatement admitted (non-reliance)historical
- 2011-03-16
- Change in certifying accountant4 occurrences
- 2020-11-06
- Late periodic report5 occurrences
- 2010-05-18
- Delisting notice / listing-rule failure2 occurrences
- 2009-05-05
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2019-06-07
- SEC comment-letter activity52 occurrences
- 2026-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 11, 2026OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month.Regulation FD disclosure · press release
- Sep 9, 2026On September 9, 2026, the Company shared 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases, including BVMD and ARB. Cohort 1 enrolled five participants treated at 1.5 x 10⁹ vg/eye: three participants …Regulation FD disclosure · Form 8-K
- Aug 6, 2026Opus Genetics Announces Financial Results for.Earnings release · press release
- Jun 16, 2026Opus Genetics Highlights Five Gene Therapy Programs Targeting.Regulation FD disclosure · press release
- Jun 16, 2026Certain statements contained in this presentation are not statements of.Regulation FD disclosure · press release
- May 12, 2026Opus Genetics Announces Financial Results for.Earnings release · press release
- Apr 24, 2026As previously disclosed, on April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent, and certain purchasers party thereto (the …New debt or off-balance-sheet obligation · Form 8-K
- Apr 7, 2026On April 1, 2026, Opus Genetics, Inc. (the “Company”) entered into a Change in Control Bonus Payment Agreement with each of Dr. George Magrath, Robert Gagnon, Joseph Schachle, and Dr. Ashwath Jayagopal, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific and Development …Director or officer change · Form 8-K
- Apr 7, 2026Note Purchase Agreement On April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent (“Purchaser Agent”), and certain purchasers …Material agreement entered · Form 8-K
- Mar 10, 2026Opus Genetics Announces Financial Results for.Earnings release · press release
- Feb 19, 2026Private Placement On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…